GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

Lawsuits against the companies began piling up in both state and federal courts after the US Food and Drug Administration in ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a ...

The pharmaceutical giant has agreed to a $2.2bn (£1.68bn) settlement to resolve lawsuits in the US alleging that the ...

Pharmaceutical giant GSK will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac ...